Bessemer Group’s Coherus Oncology CHRS Stock Holding History

Bessemer Group’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-526	Closed	-$2K	–	2161
2023 Q3	$2K	Buy	+526	New	+$2.43K	﹤0.01%	1947

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bessemer Group's CHRS Position: Q4 2023 in Review

Bessemer Group sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 526 shares — an estimated $2K sold.

Bessemer Group first reported a position in CHRS in Q3 2023 and held it in 1 quarter. The position peaked at $2K in Q3 2023. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

Bessemer Group reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
Bessemer Group sold 526 Coherus Oncology shares in Q4 2023, an estimated $2K.
Bessemer Group first reported a position in Coherus Oncology in Q3 2023 and held it in 1 quarter.
Bessemer Group's Coherus Oncology position peaked at $2K in Q3 2023.
156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Bessemer Group's 13F filing for Q4 2023, filed 9 Feb 2024.